Concepedia

A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington’s Disease (HD) (S32.009)

Rajeev Kumar, Daniel O. Claassen, Ann Mongan, Benjamin Hoehn, Ping Lin, Ellen Cahir-McFarland, Chenying Guo, Vladislav Volman, Lori K. Taylor, Priya Chandra,

Neurology · 2023 · 18 citations · 0 references

DOI

Concepts

Abstract

Report final results of ANX005-HD-01, a phase 2 study of patients with or at risk of manifest HD.